Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 5.24% is 22% above its 5-year average of 4.28%, around the middle of its 5-year range (-27.49%–36.41%).
220.11% above its 12-month average of 1.64%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 7.54%.
EBITDA MARGIN
5.24%
EBITDA MARGIN AVG TTM
1.64%
EBITDA MARGIN AVG 3Y
4.86%
EBITDA MARGIN AVG 5Y
4.28%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+220.11%
CURRENT VS 3Y AVG
+7.83%
CURRENT VS 5Y AVG
+22.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AirSculpt Technologies, Inc.
Market Cap
$134.74M
EBITDA Margin
5.24%
TTM Avg
1.64%
3Y Avg
4.86%
5Y Avg
4.28%
Market Cap
$130.05M
EBITDA Margin
4.63%
TTM Avg
-2.31%
3Y Avg
-16.32%
5Y Avg
-24.77%
Market Cap
$129.14M
EBITDA Margin
-27378.57%
TTM Avg
-16324.37%
3Y Avg
-14117.74%
5Y Avg
-9505.20%
Market Cap
$128.24M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
Market Cap
$142.11M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$142.49M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$146.66M
EBITDA Margin
-16238.30%
TTM Avg
-8929.91%
3Y Avg
-4730.54%
5Y Avg
-4730.54%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AirSculpt Technologies, Inc. (AIRS) | $134.74M | 5.24% | 1.64% | 4.86% | 4.28% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.05M | 4.63% | -2.31% | -16.32% | -24.77% |
| Entera Bio Ltd. (ENTX)vs › | $129.14M | -27378.57% | -16324.37% | -14117.74% | -9505.20% |
| Cibus, Inc. (CBUS)vs › | $128.24M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -221.15% | -221.15% | -221.15% | -221.15% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | -103.63% | -143.63% | -176.25% | -194.05% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $146.66M | -16238.30% | -8929.91% | -4730.54% | -4730.54% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -47.00% | -68.63% | -61.93% | -48.63% |
Gross Margin
57.6%
EBITDA Margin
5.2%
Operating Margin
-7.8%
Net Margin
-7.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 7.54% |
| 2026-03-31 | 5.51% |
| 2025-12-31 | 4.64% |
| 2025-09-30 | -18.67% |
| 2025-06-30 | 9.16% |
| 2025-03-31 | 4.20% |
| 2024-12-31 | -2.39% |
| 2024-09-30 | -1.68% |
| 2024-06-30 | -4.11% |
| 2024-03-31 | 29.03% |
| 2023-12-31 | 8.78% |
| 2023-09-30 | 7.66% |
| 2023-06-30 | 14.14% |
| 2023-03-31 | 8.95% |
| 2022-12-31 | -9.20% |
| 2022-09-30 | 1.59% |
| 2022-06-30 | 11.93% |
| 2022-03-31 | 1.81% |
| 2021-12-31 | -27.49% |
| 2021-09-30 | 32.50% |
| 2021-06-30 | 36.41% |
| 2021-03-31 | 33.27% |
| 2020-12-31 | 33.80% |
| 2020-09-30 | 27.36% |
| 2020-06-30 | 13.91% |
| 2020-03-31 | 13.91% |
